Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sponer, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sponer, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?

G. Sponer*

Institute of Pharmacology and Toxicology, Ruprecht-Karls-University Heidelberg, Mannheim, Germany

* Correspondence: G. Sponer, Institute of Pharmacology and Toxicology, Ruprecht-Karls-University Heidelberg, Maybachstrasse 14-16, D-68169 Mannheim, Germany.

Abstract

In the past, some non-cardiovascular drugs have been identified as prolonging repolarization and evoking torsade de pointes. Concerns prompted the health authorities to request detailed investigations targeted on this issue. In particular, in vitro and in vivo pre-clinical studies are regarded as mandatory in order to assess properly the potential risk of new compounds. However, appropriate assessment is only possible if the methods used are standardized and validated, which cannot currently be completely guaranteed. Additionally, a suitable threshold should also be specified in pre-clinical test systems. If some findings indicate prolongation of repolarization, further investigations are needed in order to evaluate the potential risk or to get more insight into the mode of action. However, withdrawal of the compound from further development at any stage is another alternative in order to spare resources and to avoid regulatory problems. In any case, a proper evaluation of the benefit-risk ratio is mandatory when findings indicate that a new compound may prolong repolarization.

Key Words: Action potential • QT prolongation • drug development

References

  1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216–1231[Free Full Text]
  2. Committee for Proprietary Medicinal Products (CPMP)^. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products CPMP 986/96. December 17, 1997. London
  3. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol. 1993;72(Suppl B):50B–52B[CrossRef][Medline]
  4. Lipicky R. A viewpoint on drugs that prolong the QTc interval. Am J Cardiol. 1993;72(Suppl B):53B–54B[CrossRef][Medline]
  5. Morgenroth J, Brown AM, Critz S, et al. Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event. Am J Cardiol. 1993;72(Suppl B):26B–31B[CrossRef][Medline]
  6. Woosley RL, Sale M. QT interval: a measure of drug action. Am J Cardiol. 1993;72(Suppl B):36B–43B[CrossRef][Medline]
  7. Garson A. How to measure the QT interval—what is normal? Am J Cardiol. 1993;72(Suppl B):1413–1613
  8. Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol. 1996;41:77–81[CrossRef][Web of Science][Medline]
  9. Eckhardt L, Haverkamp W, Borggrefe M, Breithardt G. Experimental models of torsade de pointes. Cardiovasc Res. 1998;39:178–193[Abstract/Free Full Text]
  10. Platia EV, Weisfeldt M, Franz MR. Immediate quantitation of antiarrhythmic drug effect by monophasic action potential recording in coronary artery disease. Am J Cardiol. 1988;61:1284–1287[CrossRef][Web of Science][Medline]
  11. Pourrias B, Persolt RD, Lacroix P. QT interval prolongation by noncardiovascular drugs: A proposed assessment strategy. Drug Dev Res. 1999;47:55–62[CrossRef][Web of Science]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sponer, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sponer, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?